MediGene Obtains Additional US Patent Protection
(Thomson Reuters ONE) -
MediGene AG / MediGene Obtains Additional US Patent Protection processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, September 16, 2010. The biotech company MediGene AG
(Frankfurt: MDG, Prime Standard) has obtained a patent on the manufacturing
process for the drug candidate EndoTAG(TM)-1 from the US patent office. Patent
no. 7,794,747 protects the manufacturing process used for EndoTAG(TM)-1 as well
as the product manufactured by this process. The term of the patent "Method of
producing a cationic liposomal preparation comprising a lipophilic compound"
will end on January 25, 2024.
Dr. Frank Mathias, Chief Executive Officer of MediGene AG commented: "MediGene
possesses extensive protection for EndoTAG(TM)-1 and the EndoTAG(TM) technology
in both Europe and the USA. We are delighted that now, just as is already the
case in Europe, a US patent has been granted on the EndoTAG(TM)-1 manufacturing
process, and consequently the product is also further protected. This fulfils an
important prerequisite for the future commercialization of the drug."
EndoTAG(TM)-1: EndoTAG(TM)-1 represents an innovative therapeutic approach that
has its effect by both targeted anti-vascular (i.e. against newly formed tumor
blood vessels), and anti-tumoral (directed against the tumor) mechanisms. The
drug candidate selectively attaches itself to newly developed, negatively
charged tumor blood vessels, thus attacking only these blood vessels and not
those in healthy tissue. Concurrently, EndoTAG(TM)-1 prevents the formation of
new vessels, which is expected to suppress further tumor growth. EndoTAG(TM)-1
is a combination of positively charged liposomes with the therapeutic substance
Paclitaxel embedded therein.
EndoTAG(TM)-1 is MediGene's first product candidate derived from the EndoTAG(TM)
platform technology. MediGene has achieved positive results with EndoTAG(TM)-1
in a controlled phase II clinical trial in pancreatic cancer and in another
phase II clinical trial in triple receptor-negative breast cancer. In Europe and
the USA, EndoTAG(TM)-1 has been granted orphan drug designation which provides
benefits in the drug development and approval processes. MediGene is aiming to
sign one or more partnership agreements for this product with pharmaceutical or
biotech companies in 2010.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(® )and EndoTAG(TM)( )are registered trademarks of MediGene AG. These
trademarks may be owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology
company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK
and San Diego, USA. MediGene is the first German biotech company to have drugs
on the market which are distributed by partner companies. It has several drug
candidates in clinical development and possesses innovative platform
technologies. MediGene focuses on clinical research and development of novel
drugs with a focus on oncology.
Contact MediGene AG
Email: investor(at)medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
[HUG#1444744]
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MediGene AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 16.09.2010 - 08:30 Uhr
Sprache: Deutsch
News-ID 42634
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene Obtains Additional US Patent Protection"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
